ArticleBMC cancer2026
Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo assess the association between baseline serum lipids and the risk of severe hepatic immune-related adverse events (irAEs) in solid cancer patients treated with PD-1 inhibitors.
methodsThis retrospective study included a discovery cohort (N = 601) and an independent high-risk population validation cohort (N = 331), all of whom received PD-1 inhibitor therapy at Zhongshan Hospital between 2019 and 2023. Baseline levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were measured prior to treatment. Hepatic irAEs were systematically evaluated using the CTCAE and RUCAM scores, with grade ≥ 3 (G3+) defined as severe. Restricted cubic spline models and multivariable Cox regression analyses were used to evaluate the associations between baseline lipid levels and the risk of hepatic irAEs.
resultsIn the discovery cohort, nonlinear associations were observed between baseline TC and LDL-C levels and the risk of G3+ hepatic irAEs (P-value TC=0.021, P-value LDL−C=0.034). Compared with the reference group (LDL-C: 2.47–3.37 mmol/L), patients with elevated LDL-C levels (≥ 3.37 mmol/L) had a significantly increased risk of severe hepatic irAEs (HR = 2.16, 95% CI: 1.13–4.10, P-value = 0.019). Similar associations of elevated LDL-C levels (≥ 3.37 mmol/L) were validated in the high-risk population (HR = 2.09, 95% CI: 1.01–7.73). No significant associations were found between HDL-C or TG levels and the risk of hepatic irAEs. Sensitivity analyses demonstrated consistent results, which were confirmed in the validation cohort.
conclusionsElevated baseline LDL-C levels were associated with an increased risk of severe hepatic irAEs in solid cancer patients receiving PD-1 inhibitor therapy. This finding highlights the importance of pre-treatment lipid risk stratification and monitoring in immunotherapy patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.